UPDATE
: Monday, September 7, 2020
Home
Login
Mobile Version
All
Hospital
Pharma
Bio
Korea‘s Bio Industry
Device/ICT
Policy
People
Life science
Special
Innovation for Survival
Korea’s medical culture series
Korea’s New Candidate Drug Watch List
Special Series in Celebration of KBR's 1st Anniversary
Interview with foreign envoys
Special Series in Celebration of KBR’s 2nd Anniversary
Interview with global pharma
Special Series in Celebration of KBR’s 3rd Anniversary
Special Series in Celebration of KBR’s 4th Anniversary
ASCO 2020 Highlights
Opinion
Reporter’s Notebook
Search
트위터
페이스북
RSS
상단여백
제목보기
제목보기
제목+내용
HLB to seek pre-NDA meeting with FDA for rivoceranib
by Jeong Sae-im
2019-08-06 15:43
Roche, MSD, AstraZeneca: top 3 risers on NASDAQ biotech
by Kim Yun-mi
2019-08-06 11:29
Pharmicell submits investigational new drug application for prostate cancer treatment
by Lee Han-soo
2019-08-05 17:59
Sillajen’s trouble heralds fall of one of most prominent biotech firms
by Lee Han-soo
2019-08-05 16:55
SillaJen remains confident about Pexa-Vec’s value, despite trial failure
by Jeong Sae-im
2019-08-05 14:49
라인
Suspicions resurge over SillaJen execs’ stock selling before Pexa-Vec trial suspension
by Jeong Sae-im
2019-08-05 11:26
Biotech shares tank amid SillaJen’s likely halt of Pexa-Vec trial
by Jeong Sae-im
2019-08-02 15:45
Eutilex pipelines are underrated: CEO
by Jeong Sae-im
2019-08-01 16:08
Samsung BioLogics records Q2 operating loss
by Lee Han-soo
2019-07-25 10:16
Samsung Bioepis biosimilar sales in EU top $180 million in Q1
by Lee Han-soo
2019-07-24 15:29
라인
Celltrion Healthcare joins Australia's pharma industry group
by Lee Han-soo
2019-07-22 15:13
Samsung BioLogics’ fate remains uncertain amid litigating ups and downs
by Lee Han-soo
2019-07-19 18:16
EU starts evaluating Samsung Bioepis’ sales application for Avastin biosimilar
by Lee Han-soo
2019-07-19 17:01
Celltrion targets Chinese biosimilar market through joint venture
by Lee Han-soo
2019-07-19 14:53
Biopharmaceutical stocks face grim outlook in 2H
by Jeong Sae-im
2019-07-17 14:11
라인
Celltrion starts P1 trial of Xolair biosimilar
by Lee Han-soo
2019-07-15 17:45
Doctors question Pexa-Vec+Imfinzi combo’s effect on colon cancer
by Jeong Sae-im, Kim Yun-mi
2019-07-12 15:13
Court suspends decision on ministry’s order to revoke Invossa license
by Jeong Sae-im
2019-07-12 13:11
Prosecutors raid 2 lead managers of Kolon TissueGene’s IPO
by Jeong Sae-im
2019-07-11 16:39
NKMax America seeks NASDAQ listing
by Jeong Sae-im
2019-07-11 12:41
-
1
2
3
4
5
6
7
8
9
10
다음
-
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
여백
Most viewed
1
‘Cyramza helped improve gastric cancer treatment in Korea’
2
‘Reduced-dose prasugrel effective for ACS patients undergoing PCI’
3
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
4
SNUBH develops AI model predicting patients at risk of cerebral aneurysm
5
Novavax releases encouraging phase-1 results on Covid-19 vaccine candidate
6
LG Chem, SK Bioscience end sales partnership with Daewoong
7
UBcare wins patent for tech to monitor suspected infectious diseases
8
176 civic groups furious over government-doctors deal
9
Recovered Covid-19 patients suffer from aftereffects – for long
10
Regulator OKs JW Pharma's rheumarthritis drug for treating giant cell arteries
여백
Opinion
[Column] Correct diagnosis leads to proper treatment
[Column] How ongoing doctors’ strike is different from 20 years ago
A Korean-American Doctor asks: Is Korea truly in 2020?
여백
Back to Top